Literature DB >> 28408527

The Future of Radioligand Therapy: α, β, or Both?

Uwe Haberkorn1,2, Frederik Giesel3, Alfred Morgenstern4, Clemens Kratochwil3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28408527     DOI： 10.2967/jnumed.117.190124

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  19 in total

1.  Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.

Authors:  Wen-Ting K Tsai; Kirstin A Zettlitz; Magnus Dahlbom; Robert E Reiter; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

Review 2.  α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

Authors:  Sophie Poty; Lynn C Francesconi; Michael R McDevitt; Michael J Morris; Jason S Lewis
Journal:  J Nucl Med       Date:  2018-03-15       Impact factor: 10.057

3.  Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT.

Authors:  Hendrik Rathke; Clemens Kratochwil; Ralph Hohenberger; Frederik Lars Giesel; Frank Bruchertseifer; Paul Flechsig; Alfred Morgenstern; Matti Hein; Peter Plinkert; Uwe Haberkorn; Olcay Cem Bulut
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-27       Impact factor: 9.236

Review 4.  Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

Authors:  Lukas M Carter; Sophie Poty; Sai Kiran Sharma; Jason S Lewis
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-30       Impact factor: 1.921

Review 5.  Preclinical Voxel-Based Dosimetry in Theranostics: a Review.

Authors:  Arun Gupta; Min Sun Lee; Joong Hyun Kim; Dong Soo Lee; Jae Sung Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-04-19

Review 6.  A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy.

Authors:  Uwe Holzwarth; Isaac Ojea Jimenez; Luigi Calzolai
Journal:  EJNMMI Radiopharm Chem       Date:  2018-05-30

Review 7.  Atomic Nanogenerators in Targeted Alpha Therapies: Curie's Legacy in Modern Cancer Management.

Authors:  Mareike Roscher; Gábor Bakos; Martina Benešová
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-23

Review 8.  Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.

Authors:  Urs B Hagemann; Katrine Wickstroem; Stefanie Hammer; Roger M Bjerke; Sabine Zitzmann-Kolbe; Olav B Ryan; Jenny Karlsson; Arne Scholz; Hartwig Hennekes; Dominik Mumberg; Alan S Cuthbertson
Journal:  Cancer Biother Radiopharm       Date:  2020-04-07       Impact factor: 3.099

Review 9.  Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

Authors:  Ute Hennrich; Klaus Kopka
Journal:  Pharmaceuticals (Basel)       Date:  2019-07-29

10.  Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer.

Authors:  Vanessa J Kelly; Shu-Ta Wu; Vijay Gottumukkala; Richard Coelho; Keryn Palmer; Surabhi Nair; Timothy Erick; Rahul Puri; Ohad Ilovich; Pinku Mukherjee
Journal:  Theranostics       Date:  2020-05-25       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.